XENOTHERA

📣 XENOTHERA sécurise un financement non dilutif de 4 millions d'euros de France 2030 pour son projet de traitement innovant LIS22 en lymphome T périphérique. XENOTHERA est fière d'annoncer l’obtention d’un financement de 4 millions d’euros de l’Etat dans le cadre du plan d’investissement France 2030 pour développer son projet PALT24 (Polyspecific Antibodies in Lymphoproliferative T cell disorders). Ce projet vise une maladie onco-hématologique particulièrement sévère, les lymphomes T périphériques (PTCL), pour laquelle les besoins médicaux sont cruciaux — la survie à cinq ans n’étant que de 30%. Ce soutien permettra de lancer l’essai clinique PALT1 dans l’objectif d’une autorisation d'accès précoce en France et en Europe d’ici 2027. L’anticorps polyclonal glyco-humanisé (GH-pAb) de XENOTHERA se distingue par son efficacité ciblée contre les cellules tumorales sans affecter les lymphocytes sains, une avancée majeure pour le traitement des PTCL. Déjà reconnu comme « médicament orphelin » par la FDA et l’EMA, il offre un espoir inédit pour les patients. 🎯 Une avancée stratégique pour l’oncologie et les biotechnologies en France ! #France2030 #InnovationSanté #Biotechnologie #Oncologie #TraitementCancer #LymphomeT #RechercheMédicale #EssaisCliniques

📣 XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma. XENOTHERA is proud to announce the securing of a €4 million financing from the public investment program France 2030 to develop its PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders). This project aims a particularly agressive onco-hematologic disease with high unmet medical needs : PTCL, as the five year survival rate remains at only 30%. This financing will enable us to launch the PALT1 clinical trial and pursue early access authorization in France and Europe by 2027. XENOTHERA's polyclonal glyco-humanized antibody (GH-pAb) is unique in its ability to target tumor cells selectively without affecting healthy lymphocytes, a major advancement in PTCL treatment. Already recognized as an “orphan drug” by both the FDA and EMA, it brings unprecedented hope for patients. 🎯A strategic breakthrough for oncology and French biotechnologies! #France2030 #HealthInnovation #Biotechnology #Oncology #CancerTreatment #LymphomaT #MedicalResearch #PALT24 #ClinicalTrials #OrphanDrugs #XENOTHERA #PolyclonalAntibodies

📣 #Cancer #Pancreas #Treatment | Introducing a new hope for pancreatic cancer treatment with XON11. XON11, the new multi-target antibody developed by XENOTHERA, shows remarkable antitumor efficacy against pancreatic cancer cells, including those resistant to Gemcitabine, a standard therapy. With an IC50 below 50 µg/ml and two powerful mechanisms of action—complement-dependent cytotoxicity and apoptosis—XON11 targets tumor cells by activating immune proteins and both internal and external signals. ✅ Tested on a spheroid model and in a mouse model of pancreatic adenocarcinoma, XON11 demonstrated more than 50% tumor growth inhibition over three weeks with no toxicity, unlike Gemcitabine, which resulted in a 20% mortality rate in treated mice. These findings, presented at the Barcelona congress, bring new hope for the 500,000 new patients each year who face this aggressive cancer, with a five-year survival rate still very low. Odile Duvaux, President and Co-founder of XENOTHERA, commented: “XON11 strengthens our oncology portfolio, which already includes a product in the clinic, XON7, in phase I/II since 2023, with an excellent safety profile in patients. We are fully committed to fighting the dreaded pancreatic cancer, and I sincerely hope that these initial results will one day lead to a treatment for patients, which is so important." 🔍 More details in our press release below. #biotech #innovation

📣 #Cancer #Pancréas #Traitement | Nous présentons un nouvel espoir de traitement dans le cancer du pancréas grâce au XON11. Le XON11, nouvel anticorps multicible issu de la plateforme de XENOTHERA, se distingue par son efficacité antitumorale sur les cellules cancéreuses pancréatiques, y compris celles résistantes à la Gemcitabine, un traitement standard. Avec un IC50 inférieur à 50 µg/ml et deux mécanismes d’action puissants (cytotoxicité dépendante du complément et apoptose), le XON11 détruit les cellules tumorales par l’activation des protéines immunitaires et des signaux internes/externes de la cellule. ✅ Testé in vitro sur un modèle sphéroïde et in vivo sur un modèle d’adénocarcinome chez la souris, le XON11 a montré une réduction de la croissance tumorale de plus de 50 % pendant trois semaines sans toxicité, contrairement à la Gemcitabine, qui entraîne une mortalité de 20 % chez les souris. Ces résultats, présentés lors du congrès de Barcelone, représentent une véritable lueur d’espoir pour les 500 000 nouveaux patients annuels touchés par ce cancer agressif, dont le taux de survie estimé à cinq ans est seulement de 7%. Odile Duvaux, Présidente et cofondatrice de XENOTHERA, a commenté : « Le XON11 renforce notre portefeuille en oncologie, déjà doté d’un produit en clinique, le XON7, en phase I/II depuis un an, avec un profil de sécurité excellent chez les patients. Nous mobilisons ainsi toute notre énergie dans la lutte contre le redoutable cancer du pancréas, et j’espère de tout cœur que ces résultats initiaux pourront un jour donner lieu à un traitement pour les patients." 🔍 Plus de détails dans notre communiqué de presse ci-dessous. #biotech #innovation

XENOTHERA will be attending the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), taking place in Barcelona this week ! 🌍 📅 When: 23-25 th of October 2024 📍 Where: CCIB, Barcelona At ENA 2024, our CSO Firas Bassissi will be presenting on October 25th our first results on pancreas cancer, highlighting our innovative approach to tackling one of the most challenging forms of cancer. This marks a significant milestone in our mission to advance cancer therapeutics and improve patient outcomes. We’re thrilled to participate in the cutting-edge discussions and share how XENOTHERA is contributing to advancements in cancer therapeutics. 👉 Don’t miss this opportunity to connect with us this Friday as we work together to shape the future of cancer research and drug development. #ENA2024 #XENOTHERA #CancerResearch #PancreaticCancer #DrugDevelopment #MolecularTargets #InnovationInScience #Pharmaceuticals

🔴 World Organ Donation Day - The Global Kidney Shortage : A Growing Health Crisis Millions are impacted by the global kidney shortage, with over 2 million people on dialysis or waiting for a transplant. Yet, only 100,000 kidney transplants are performed annually, leaving many waiting 5 to 10 years or more, and tens of thousands dying each year while waiting. Living donors help, but they account for just 30% of transplants globally. 🔬 XENOTHERA is driving game-changing innovation to address issues in transplantation, by enabling polyclonal antibodies to reduce rejection risks. These antibodies are multispecific, meaning they can target a wide range of epitopes, combining multiple mechanisms of action for maximum efficiency. #XENOTHERA #KidneyTransplant #PolyclonalAntibodies #Biotechnology #Xenotransplantation #OrganDonation #SaveLives

🚀 ESMO 2024 : Les avancées révolutionnaires en oncologie 🔬 À l’occasion de l'ESMO 2024, Jean-Yves Blay, figure incontournable en oncologie, président de la fondation Unicancer et membre du conseil scientifique de XENOTHERA, a mis en lumière les nouvelles approches thérapeutiques prometteuses pour les patients atteints de cancer : 🔹️Immunothérapie : Améliorations pour un traitement plus ciblé et efficace. 🔹️Biomarqueurs : Nouveaux outils pour une meilleure prédiction de la réponse aux traitements. 🔹️Médecine personnalisée : Vers une approche individualisée du soin pour chaque patient. #Oncologie #ESMO2024 #InnovationSanté #RechercheMédicale #JeanYvesBlay #MédecinePersonnalisée https://lnkd.in/gMHNEMrJ

🌐 #XENOSPHERE: advancing infectious disease treatments with GH-pAbs 🧬 XENOTHERA's innovative GH-pAb platform is making significant strides in the fight against infectious diseases with XAV03, XAB05, XAB06, and XAV19. These polyclonal antibodies are tailored to address critical needs in bacterial and viral infections. 👉 Swipe through our carousel to learn more about these groundbreaking therapies and their impact on infectious disease treatment. ➡️ To find out more about XENOTHERA, please visit our website: www.xenothera.com #Innovation #Biotech #InfectiousDiseases #Immunology #COVID19 #Bacterialinfections #XAV03 #XAB05 #XAB06 #XAV19

🌐 #XENOSPHERE: understanding the Mechanisms Of Action (MOA) of GH-pAbs 🧬 At XENOTHERA, our Glyco-Humanized Polyclonal Antibodies (GH-pAbs) showcase diverse mechanisms of action that set them apart in the field of immunotherapy. The Fab region targets antigens, blocking receptors or ligands, while the Fc region triggers several biological activities like CDC, ADCC, ADCP, and apoptosis. These multifaceted actions enable GH-pAbs to suppress unwanted immunity, destroy tumoral cells, and neutralize bacteria and viruses. 👉 Swipe through our carousel to discover the science behind GH-pAbs and their multifaceted mechanisms. ➡️ To learn more about our groundbreaking technology and mission, visit our website: www.xenothera.com #Innovation #Biotech #Healthcare #Immunology #Antibodies #MOA #GHpAbs

🌐 #XENOSPHERE: spotlight on XON5 & XON9 in our pipeline 🧬 XENOTHERA's GH-pAb platform continues to expand with XON5 and XON9, two innovative anti-tumoral antibodies. While XON7 targets major cancers such as lung, prostate, ovarian, and pancreatic, XON5 and XON9 are designed to target different solid tumors through unique tumoral antigens. Both XON5 and XON9 have completed preclinical studies, demonstrating their potential in oncology. ➡️ To find out more about XENOTHERA, please visit our website: www.xenothera.com #Innovation #Biotech #Healthcare #Immunology #Oncology #CancerTreatment #XON5 #XON9